The gap between trailing and forward P/E suggests the market expects earnings to rebuild over the next year, which is consistent with the recent EPS shortfall against estimate. A PEG of 7.9 indicates the current price assumes growth substantially faster than the reported 11.5% revenue expansion can justify on its own. Investors should monitor whether the multiple holds if TMTT adoption disappoints, since the valuation appears to rely on the structural heart franchise being priced as a pure-play growth asset.

The stability of gross margin points to durable pricing power in the valve franchise, which is difficult for peers to replicate. The sharp operating margin decline without a matching gross margin move suggests operating expense growth, likely in clinical and selling costs, is absorbing gross profit faster than revenue scales. Net margin of 17.9% in the latest quarter trails Stryker's 12.9% only modestly on an absolute basis, so earnings power depends heavily on whether SG&A discipline returns.

Goodwill rising from $1.2B to $2.0B alongside a low ROIC profile suggests recent acquisitions have diluted the return on invested capital rather than enhancing it. ROE readings are distorted by a large equity base and a single anomalous quarter, so ROIC is the more reliable gauge. Whether returns can compound toward peer levels depends on the operating margin recovering, which has not yet been demonstrated in the reported data.

Leverage is negligible relative to peers and the company's own equity base, which reduces covenant and refinancing risk to a low level based on the supplied data. Interest coverage is not reported in the provided ratio set, so debt service capacity can only be inferred from the low debt load rather than measured directly. The more relevant balance sheet question is whether the goodwill base remains recoverable, not whether debt is manageable.